Retreatment with peptide receptor radionuclide therapy in patients with progressing neuroendocrine tumours: efficacy and prognostic factors for response.

CONCLUSION: PRRT retreatment is safe and offers patients, who had progressed following initial PRRT course, a reasonably good PFS. Extra consideration is needed in patients with multiple comorbidities, as they may be at greater risk of renal and haematological toxicity. Male sex and high burden of liver metastases seem to be associated with shorter PFS following PRRT retreatment. Advances in knowledge: The majority of studies on PRRT have shown that it is effective as an initial treatment. This study with long term follow-up demonstrates that PRRT is safe and effective retreatment option in patients that have progressed following initial PRRT course. PMID: 29513039 [PubMed - as supplied by publisher]
Source: The British Journal of Radiology - Category: Radiology Authors: Tags: Br J Radiol Source Type: research